NASDAQ:INDP - Indaptus Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.00
  • Forecasted Upside: 207.10 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$5.21
▼ -0.21 (-3.87%)

This chart shows the closing price for INDP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Indaptus Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INDP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INDP

Analyst Price Target is $16.00
▲ +207.10% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Indaptus Therapeutics in the last 3 months. The average price target is $16.00, with a high forecast of $16.00 and a low forecast of $16.00. The average price target represents a 207.10% upside from the last price of $5.21.

This chart shows the closing price for INDP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Indaptus Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/4/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/19/2021Maxim GroupUpgradeHold ➝ Buy$16.00Medium
(Data available from 12/4/2016 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/6/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/5/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/5/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/4/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/4/2021

Current Sentiment

  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Indaptus Therapeutics logo
Indaptus Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on research and development and clinical trials. The company develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing efficient gastric retention. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.
Read More

Today's Range

Now: $5.21
Low: $4.88
High: $5.40

50 Day Range

MA: $7.37
Low: $5.21
High: $11.58

52 Week Range

Now: $5.21
Low: $4.88
High: $28.83

Volume

268,278 shs

Average Volume

211,463 shs

Market Capitalization

$42.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

Frequently Asked Questions

What sell-side analysts currently cover shares of Indaptus Therapeutics?

The following equities research analysts have issued research reports on Indaptus Therapeutics in the last twelve months: Maxim Group.
View the latest analyst ratings for INDP.

What is the current price target for Indaptus Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Indaptus Therapeutics in the last year. Their average twelve-month price target is $16.00, suggesting a possible upside of 207.1%. Maxim Group has the highest price target set, predicting INDP will reach $16.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $16.00 for Indaptus Therapeutics in the next year.
View the latest price targets for INDP.

What is the current consensus analyst rating for Indaptus Therapeutics?

Indaptus Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INDP will outperform the market and that investors should add to their positions of Indaptus Therapeutics.
View the latest ratings for INDP.

What other companies compete with Indaptus Therapeutics?

How do I contact Indaptus Therapeutics' investor relations team?

Indaptus Therapeutics' physical mailing address is 12 Hartom Street, Har Hotzvim, Jerusalem 777512. The company's listed phone number is (646) 374-8050 and its investor relations email address is [email protected] The official website for Indaptus Therapeutics is intecpharma.com.